New drug cocktail shows promise for Hard-to-Treat myeloma

NCT ID NCT02199665

Completed Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a combination of three drugs—selinexor, carfilzomib, and dexamethasone—in 52 patients with multiple myeloma that had returned or stopped responding to treatment. The main goal was to find the safest dose and check for side effects. Researchers hope this combination could offer a new option for patients with few alternatives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: selinexor, carfilzomib, and dexamethasone
What this could lead to: If successful, this could lead to a new treatment option for patients with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is an early Phase I trial with only 52 participants, focused on finding the right dose and checking safety. It is not yet proven to work, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Mayo Clinic (AZ)

Scottsdale, Arizona, 85259, United States
Mount Sinai Medical Center

New York, New York, 10029, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109, United States
Wayne State University Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.